---
title: "Gian Lifecare Ltd (542918) — Share Price, Financials & Analysis"
symbol: "542918"
company: "Gian Lifecare Ltd"
canonical: "https://tapetide.com/stocks/542918"
isin: "INE063601012"
nse_symbol: "GIANLIFECARELTD"
bse_code: "542918"
sector: "Healthcare Services"
industry: "Healthcare Service Provider"
market_cap_cr: 4.9
generated_at: "2026-09-13T20:15:59.419Z"
---

# Gian Lifecare Ltd (542918)

Canonical page: https://tapetide.com/stocks/542918

## Company

- **NSE Symbol:** GIANLIFECARELTD
- **BSE Code:** 542918
- **ISIN:** INE063601012
- **Sector:** Healthcare Services
- **Industry:** Healthcare Service Provider
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2020-01-13
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** gianpathlabs.com

## About

Incorporated in 2018, Gian Lifecare Ltd is in the business of independent diagnostic/pathological laboratories[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:39:54.468202Z.

- **Market Cap:** ₹4.9 Cr
- **Classification:** Microcap
- **P/E (reported):** -5.2
- **EPS (TTM):** ₹-0.92
- **EPS (reported):** ₹4.02
- **Book Value:** ₹18.15
- **Price to Book:** 0.26
- **Dividend Yield:** 0%
- **ROE:** -0.19%
- **ROCE:** 2.36%
- **Debt to Equity:** 0.3
- **Revenue (yearly):** ₹6.9 Cr
- **Net Income:** ₹0 Cr
- **EBITDA:** ₹1.2 Cr
- **52-Week High:** ₹16.79
- **52-Week Low:** ₹4.55
- **RSI (14):** 46.48

## Tapetide Score

- **Score:** 36 / 100
- **Score date:** 2026-09-04
- **Archetype:** Weak and Under Pressure
- **What it means:** Weak financials are the defining feature, and neither the valuation nor the trend reading is strong enough to offset them. Worth reading the risk flags and recent filings closely before anything else.
- **Pillar profile:** Quality: Weak · Valuation: Fair · Momentum: Falling
- **Percentile:** 7.3 (of 4473 scored stocks)
- **Confidence:** 91%
- **Data coverage:** 81%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 27.53 | 9% |
| growth | 1.36 | 9% |
| momentum | 8.79 | 12% |
| ownership | 40.39 | 24% |
| quality | 48.4 | 22% |
| valuation | 52.09 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Stock is trading at 0.26 times its book value

### Weaknesses

- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -1.92%
- Promoter holding is low: 30.2%
- Company has a low return on equity of 10.1% over last 3 years.
- Promoters have pledged 65.1% of their holding.
- Company has high debtors of 374 days.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -61.43% | -87.84% | -99.65% |
| ebitda margin growth | 200% | -65.03% | -14.2% | — |
| net income growth | 120% | -100% | -100% | — |
| revenue growth | 50% | -50% | -27% | — |
| roce | -153.49% | -91.42% | -79.58% | — |
| roe | -119.61% | -100.88% | 9.46% | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 1.55 | 2.43 | 2.3 | 3.79 | 4.6 | 1.98 | 1.95 | 1.59 | 1.11 | 0.87 | 0.66 | 1.12 |
| Expenses | 2.31 | 1.92 | 1.97 | 1.59 | 1.55 | 1.76 | 1.74 | 1.12 | 1.12 | 0.74 | 1.07 | 0.87 |
| Operating Profit | -0.76 | 0.51 | 0.33 | 2.2 | 3.05 | 0.22 | 0.21 | 0.47 | -0.01 | 0.13 | -0.41 | 0.25 |
| OPM % | -49.03 | 20.99 | 14.35 | 58.05 | 66.3 | 11.11 | 10.77 | 29.56 | -0.9 | 14.94 | -62.12 | 22.32 |
| Other Income | 0.18 | 0.14 | 0.15 | 0.19 | 0.18 | 0.19 | 0.17 | 0.16 | -0.24 | 0.15 | 0.09 | 0.09 |
| Interest | 0.11 | 0.12 | 0.11 | 0.14 | 0.1 | 0.14 | 0.12 | 0.12 | 0.13 | 0.09 | 0.12 | 0.15 |
| Depreciation | 0.12 | 0.13 | 0.13 | 0.16 | 0.11 | 0.12 | 0.12 | 0.12 | 0.27 | 0.11 | 0.11 | 0.11 |
| Profit before tax | -0.81 | 0.4 | 0.24 | 2.09 | 3.02 | 0.15 | 0.14 | 0.39 | -0.65 | 0.08 | -0.55 | 0.08 |
| Tax % | 17.28 | 35 | 16.67 | 25.36 | 29.47 | 40 | 14.29 | 10.26 | -7.69 | 37.5 | -7.27 | -37.5 |
| Net Profit | -0.95 | 0.26 | 0.2 | 1.55 | 2.13 | 0.09 | 0.12 | 0.35 | -0.6 | 0.05 | -0.51 | 0.1 |
| EPS in Rs | -0.92 | 0.25 | 0.19 | 1.5 | 2.06 | 0.09 | 0.12 | 0.34 | -0.58 | 0.05 | -0.49 | 0.1 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
| --- | --- | --- | --- | --- | --- |
| Sales | 15.45 | 11.41 | 12.78 | 5.94 | 3.76 |
| Expenses | 9.39 | 9.56 | 6.63 | 4.98 | 3.8 |
| Operating Profit | 6.06 | 1.85 | 6.15 | 0.96 | -0.04 |
| OPM % | 39.22 | 16.21 | 48.12 | 16.16 | -1.06 |
| Other Income | 0.51 | 0.69 | 0.67 | 0.26 | 0.09 |
| Interest | 0.39 | 0.45 | 0.54 | 0.55 | 0.49 |
| Depreciation | 0.33 | 0.5 | 0.53 | 0.63 | 0.6 |
| Profit before tax | 5.85 | 1.59 | 5.75 | 0.04 | -1.04 |
| Tax % | 25.3 | 33.33 | 27.65 | 200 | — |
| Net Profit | 4.37 | 1.06 | 4.15 | -0.04 | -0.96 |
| EPS in Rs | 4.23 | 1.02 | 4.01 | -0.04 | -0.92 |
| Dividend Payout % | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
| --- | --- | --- | --- | --- | --- |
| Equity Capital | 10.34 | 10.34 | 10.34 | 10.34 | 10.34 |
| Reserves | 3.69 | 4.78 | 8.93 | 8.89 | 8.43 |
| Borrowings | 2.03 | 4.57 | 4.88 | 5.84 | 5.73 |
| Other Liabilities | 7 | 8.56 | 8.48 | 10.86 | 9.65 |
| Total Liabilities | 23.06 | 28.25 | 32.63 | 35.93 | 34.15 |
| Fixed Assets | 3.5 | 4.62 | 5.07 | 4.45 | 4.22 |
| CWIP | 0.12 | 0.14 | 0.14 | 0.14 | 0.14 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 19.44 | 23.49 | 27.42 | 31.34 | 29.79 |
| Total Assets | 23.06 | 28.25 | 32.63 | 35.93 | 34.15 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
| --- | --- | --- | --- | --- |
| Cash from Operating Activity | 5.79 | 2.22 | 0.7 | 0.27 |
| Cash from Investing Activity | -4.12 | -0.94 | -0.32 | 0.25 |
| Cash from Financing Activity | 0.67 | -0.37 | -0.16 | 0.45 |
| Net Cash Flow | 2.34 | 0.91 | 0.22 | 0.97 |
| Free Cash Flow | 4.83 | 0.59 | -0.28 | 0.26 |
| CFO/OP | 107 | 121 | 12 | 31 |

### Ratios

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
| --- | --- | --- | --- | --- |
| Debtor Days | 42.05 | 103.97 | 137.37 | 374.22 |
| Cash Conversion Cycle | 42.05 | 103.97 | 137.37 | 374.22 |
| Working Capital Days | -31.66 | -161.55 | -81.4 | -75.58 |
| ROCE % | — | 11.41 | 28.7 | 2.4 |

## Shareholding Pattern

### Quarterly

| Category | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 53.1% | 53.1% | 51.73% | 48.47% | 32.82% | 31.99% | 32.09% | 32.09% | 32.09% | 32.09% | 32.09% | 30.17% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 38.51% | 37.2% | 38.46% | 40.36% | 56.34% | 56.62% | 57.66% | 57.72% | 57.96% | 54.15% | 54.05% | 53.47% |
| Others | 8.38% | 9.69% | 9.81% | 11.18% | 10.84% | 11.39% | 10.24% | 10.17% | 9.93% | 13.75% | 13.85% | 16.35% |
| No. of Shareholders | 1336 | 2098 | 2092 | 2426 | 3349 | 3863 | 4298 | 4382 | 4363 | 4285 | 4217 | 4243 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 1 / 6 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 4.81 | Sell |
| EMA (10) | 4.79 | Sell |
| SMA (20) | 4.82 | Sell |
| EMA (20) | 4.81 | Sell |
| SMA (50) | 4.84 | Sell |
| EMA (50) | 4.95 | Sell |
| SMA (100) | 5.29 | Sell |
| EMA (100) | 5.56 | Sell |
| SMA (200) | 7 | Sell |
| EMA (200) | 7.28 | Sell |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 42.15 | Neutral |
| MACD (12,26,9) | -0.03 | Sell |
| Stochastic (14,3,3) | 48.21 | Neutral |
| ADX (14) | 21.79 | Neutral |
| Williams %R (14) | -70 | Neutral |
| ATR (14) | 0.25 | High Volatility |
| ROC (12) | -3.31 | Sell |
| Stoch RSI (14) | 0 | Buy |
| UO (7,14,28) | 68.53 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-04-21 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=566ca223-227d-4845-8a51-14e7d2e5526a.pdf) |
| 2026-03-04 | [Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 Regarding Approval To Enter Into Hospital Lab Management Services With M/S. Brahma Hospital (HUF)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d674ee04-1399-4afb-a706-c66e5b0bec67.pdf) |
| 2026-02-14 | [Board Meeting Outcome for Outcome Of Board Meeting Held On Saturday February 14 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5e85a151-f27f-476f-9919-ced4c20eb704.pdf) |
| 2026-02-09 | [Board Meeting Intimation for Intimation Of Board Meeting To Consider And Approve Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter/ Period Ended On 31St December 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f03f8c93-853b-46da-ab00-71895a21a88c.pdf) |
| 2026-01-28 | [Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday January 28 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=08a7f8a8-b797-4eb0-8070-4c5b22923dae.pdf) |
| 2026-01-24 | [Board Meeting Intimation for Rescheduling Of Board Meeting To Consider And Approve Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter/ Period Ended 30Th September 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a320a0cd-d1ff-465d-9561-323311b9373c.pdf) |
| 2026-01-21 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1c7a7e75-320d-41ed-ae1b-0475b3706d6e.pdf) |
| 2026-01-21 | [Board Meeting Intimation for Rescheduling Of Board Meeting To Consider And Approve Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter/ Period Ended 30Th September 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b528bccd-b459-4d97-a8cc-a1eb25bfc266.pdf) |
| 2026-01-15 | [Board Meeting Intimation for Intimation Of Board Meeting To Consider And Approve Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter/ Period Ended 30Th September 2025 And 31St December 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=61ccb140-3689-4cba-98e4-1184dfefa165.pdf) |
| 2025-10-18 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=63cf9883-06c4-4e19-b1d1-0b9afba4149b.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Feb - Board meeting 14 Feb 2026 to approve unaudited results for quarter ended 31 Dec 2025; trading window closed. | [Board Meeting Intimation for Intimation Of Board Meeting To Consider And Approve Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter/ Period Ended On 31St December, 2025 9 Feb - Board meeting 14 Feb 2026 to approve unaudited results for quarter ended 31 Dec 2025; trading window closed.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f03f8c93-853b-46da-ab00-71895a21a88c.pdf) |
| 4 Mar - Approved 5-year lab management tie-up with M/s. Brahma Hospital from March 1, 2026; ~INR1 Cr revenue, INR18-20L profit annually. | [Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 Regarding Approval To Enter Into Hospital Lab Management Services With M/S. Brahma Hospital (HUF) 4 Mar - Approved 5-year lab management tie-up with M/s. Brahma Hospital from March 1, 2026; ~INR1 Cr revenue, INR18-20L profit annually.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d674ee04-1399-4afb-a706-c66e5b0bec67.pdf) |
| 21 Apr - Submitted Regulation 74(5) depository certificate for quarter ended March 31, 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 21 Apr - Submitted Regulation 74(5) depository certificate for quarter ended March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/566ca223-227d-4845-8a51-14e7d2e5526a.pdf) |
| 14 Feb - Board approved unaudited results for Dec 31, 2025; auditor noted Rs743.78L cash, Rs426.66L dues, Rs359.78L NPA. | [Board Meeting Outcome for Outcome Of Board Meeting Held On Saturday, February 14, 2026 14 Feb - Board approved unaudited results for Dec 31, 2025; auditor noted Rs743.78L cash, Rs426.66L dues, Rs359.78L NPA.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5e85a151-f27f-476f-9919-ced4c20eb704.pdf) |
| 14 Feb - Board approved quarter results; auditor flagged Rs.743.78 lakh cash, Rs.426.66 lakh dues, Rs.359.78 lakh NPA. | [Outcome Of Board Meeting Held On Saturday, February 14, 2026 14 Feb - Board approved quarter results; auditor flagged Rs.743.78 lakh cash, Rs.426.66 lakh dues, Rs.359.78 lakh NPA.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5d848506-bef8-403e-ad97-5c2413e5b356.pdf) |
| 13 Feb - Shilpa Bung resigned as Independent Director effective 13-Feb-2026; cited ICSI chairperson role. | [Announcement under Regulation 30 (LODR)-Resignation of Director 13 Feb - Shilpa Bung resigned as Independent Director effective 13-Feb-2026; cited ICSI chairperson role.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1c7655cc-db32-4a44-84eb-b5b690001849.pdf) |
| 13 Feb - Board reconstituted Audit, Stakeholders' Relationship, Nomination & Remuneration Committees on Feb 13, 2026; members listed. | [Intimation Of Reconstitution Of Audit Committee, Stakeholders Relationship Committee And Nomination And Remuneration Committee Under Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirement) Regulations, 2015. 13 Feb - Board reconstituted Audit, Stakeholders' Relationship, Nomination & Remuneration Committees on Feb 13, 2026; members listed.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0d51801b-3733-4244-9035-7f0511ebe2b3.pdf) |
| 13 Feb - Approved unaudited Q3/9M results (Dec 31, 2025); approved Helios investment; director appointment/resignation; committees reconstituted. | [Board Meeting Outcome for Outcome Of Board Meeting Held On Friday, February 13, 2026 Of Prudential Sugar Corporation Limited. 13 Feb - Approved unaudited Q3/9M results (Dec 31, 2025); approved Helios investment; director appointment/resignation; committees reconstituted.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/91353023-4998-4b71-8568-768332ca8024.pdf) |
| 13 Feb - Appointed Ms. Priyanka Rajora as Independent Woman Director, Feb 13, 2026–Feb 12, 2031; shareholder approval pending. | [Announcement under Regulation 30 (LODR)-Change in Management 13 Feb - Appointed Ms. Priyanka Rajora as Independent Woman Director, Feb 13, 2026–Feb 12, 2031; shareholder approval pending.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ba418768-3e4e-447b-b89f-7d634d8b26c4.pdf) |
| 11h - Submitted Regulation 74(5) depository certificate for quarter ended March 31, 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 11h - Submitted Regulation 74(5) depository certificate for quarter ended March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/566ca223-227d-4845-8a51-14e7d2e5526a.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-02-14 | [Outcome Of Board Meeting Held On Saturday February 14 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5d848506-bef8-403e-ad97-5c2413e5b356.pdf) |
| 2026-01-28 | [Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter/ Half Year Ended 30Th September 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=090e0f55-b700-4c60-ad25-e378dd585e00.pdf) |
| 2025-09-02 | [Results For Financial Year 01/04/2024-31/03/2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=545097a8-1704-4824-8ed0-260b7b2d975c.pdf) |
| 2025-09-02 | [Results For Quarter Ended June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0bf1489e-5bb5-46d7-9920-d01cb18cadff.pdf) |
| 2025-07-17 | [Outcome Of Board Meeting Held On Friday February 14 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ea83c3bb-4e59-4aa6-b75f-858efbb2bea8.pdf) |
| 2024-11-14 | [Outcome Of Board Meeting Held On Thursday, November 14, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1bccd0ac-c3c4-43b6-b4eb-8059a3d4e310.pdf) |
| 2024-08-14 | [Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter/ Period Ended June 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c713d9be-5323-46df-9be2-f7357c6d61f3.pdf) |
| 2024-05-30 | [Audited Standalone And Consolidated Financial Results Of The Company For The Quarter/ Half Year And Year Ended 31St March, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0b757249-c5d3-4b7e-9ace-d0e579a3c579.pdf) |
| 2024-01-13 | [Financial Results For The Quarter Ended 31/12/2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c0ecbcdb-8059-4aca-8073-3dda29be2b72.pdf) |
| 2023-11-11 | [Results For The Period Ended September 30, 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5d9067f8-c45b-4f42-8b5e-c9fed9f42012.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bdb69e89-f138-4f28-9310-ae5f6b2e5b5c.pdf) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3cd947b0-ce6b-4255-93f8-ed2e7d45161b.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e537b4ea-3e05-46ad-8f07-449e26d16654.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2b4490c7-07a9-4239-8f72-cd80dc313609.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/29dde1b5-adc7-404e-b18e-a04459c2f76d.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b6199a5e-55c3-4404-b372-c1b39323839d.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/542918/77236542918.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/500342/77068500342.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/542918/72049542918_19_10_21.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/500342/72453500342_11_09_21.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2021-11-16 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5533996a-82da-47e1-a5dc-63262acf7815.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2021 | [Concall - Nov 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5533996a-82da-47e1-a5dc-63262acf7815.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T20:15:59.419Z.